Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 12, 2008

View Archived Issues

Stanford University identifies two potential drug targets to treat malaria

Transcutaneous immunization effective in protecting against enterohemorrhagic E. coli infection

New antiinfective agents described in recent GSK patents

Activation of the unfolded protein response central in the pathogenesis of Charcot-Marie-Tooth 1B

Trophos receives grant to evaluate TRO-19622 in Parkinson's disease

Cogentus appoints Scientific Steering Committee for CGT-2168 phase III clinical program

University of Adelaide awarded AUD 2 million grant for five-year hepatitis C project

Toyama Chemical initiates phase II trial of T-5224 for rheumatoid arthritis

Takeda profiles Q3 developments

Risperidone long-acting injection delays relapse in bipolar disorder

Studies show aripiprazole efficacy in pediatric psychological disorders

Recent patents impart novel therapeutic agents for respiratory disorders

New antiinfective agents reported in recent patents

OctoPlus and Biolex commence phase IIa Locteron study in hepatitis C

MGCD-0103 receives orphan drug designation for acute myelogenous leukemia

Merck KGaA and Novo Nordisk disclose new diabetes compounds in recent patent literature

Pharmacopeia selects novel chemokine receptor antagonist for development

TopoTarget clarifies collaboration with Leo Pharma

Sosei commences AD-923 phase III studies in Europe

Promising interim results reported from phase III Zadaxin trial in hepatitis C

Symbollon Pharmaceuticals completes phase III trial of IoGen for fibrocystic breast disease

Solstice Neurosciences responds to FDA early communication regarding Myobloc for cervical dystonia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...